[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-sinusitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-sinusitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100579465","phase-4-biologics-in-chronic-rhinosinusitis-with-nasal-polyposis-100579465",false,"NCT06824649","Biologics in Chronic Rhinosinusitis With Nasal Polyposis","SMART Use of Biologics in Chronic Rhinosinusitis With Nasal Polyposis","CRSwNP","Inclusion Criteria:\n\n* Age \\> 18 years\n* Confirmed diagnosis of chronic rhinosinusitis with nasal polyposis using ICAR-21 (International Consensus Statement 20215) criteria\n* Bilateral nasal polyposis visible on sinonasal endoscopy\n* Nasal polyp score \\> 5\n* Baseline SNOT-22 total score \\> 30\n* Patient elects biologic therapy for the management of CRSwNP\n* Capable of receiving all 3 biologic therapy medications.\n* Treatment with intranasal mometasone ≥200 μg. once daily (or equivalent of another intranasal corticosteroid) for 1-month prior to baseline visit.\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant to give written informed consent or comply with study protocol\n* Endoscopic sinus surgery within 6-months preceding enrollment \u002F randomization.\n* Oral corticosteroid use within 30-days preceding enrollment \u002F randomization.\n* Serum IgE level outside the dosing range for omalizumab (i.e., \\\u003C30 IU\u002Fml. or a weight-based dose with insufficient data to determine dose as per FDA dosing chart)\n* Comorbid atopic dermatitis, urticaria, or any other condition that would require a specific biologic per the standard of care.\n* Currently pregnant or plan to become pregnant within the 6 months after enrollment \u002F randomization.\n* Any previous treatment with any of the 3 biologic medications.\n* Comorbid cystic fibrosis, CVID, or ciliary dyskinesia.\n* Comorbid systemic inflammatory disorders (e.g., GPA, EGPA, Sarcoidosis, SLE)\n* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks for participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.","ALL","18 Years",{"count":20,"type":21},504,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The prevalence of Chronic Sinusitis with Nasal Polyps (CRSwNP) in the United States is estimated at roughly 4%, which equates to over 13 million Americans. Until recently, the only medical treatment options available for patients with CRSwNP were corticosteroids, with surgery reserved for medical failure. The development of biologic medications over the last 5 years has revolutionized the treatment of CRSwNP. Three biologic medications have been FDA approved and available for the treatment of CRSwNP: dupilumab, omalizumab, and mepolizumab. However, data from the clinical trials for these drugs do not show universal improvement across all patients with CRSwNP. In fact, there is a wide range of outcomes for patients in these trials. The result is that clinicians have no way of knowing which specific biologic would be the best option for any given patient, nor do they know whether biomarkers can be used to predict response to biologics. It is hoped that findings from this study will inform whether any one biologic has superior outcomes to another and whether clinicians can identify patients at baseline who are most likely to improve on biologic therapy.",[27,28],"Chronic Sinusitis","Nasal Polyps",[30,31],"Sinusitis","Biologics","RECRUITING","2026-06-08",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":36},"2026-06-03",{"date":40,"type":21},"2030-02",{"name":42,"class":43},"Medical University of South Carolina","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100604576","efficacy-of-bee-venom-phonophoresis-in-treating-chronic-sinusitis-100604576","NCT07151313","Efficacy of Bee Venom Phonophoresis in Treating Chronic Sinusitis:","Efficacy of Bee Venom Phonophoresis in Treating Chronic Sinusitis: A Double-Blind Randomized Controlled Trial","BEE-SONIC","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Clinical diagnosis of chronic sinusitis (symptoms ≥ 12 weeks) or acute sinusitis confirmed by an otolaryngologist.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to bee venom or bee products.\n* Skin conditions (e.g., eczema, dermatitis, open wounds) over the area of ultrasound application.\n* Severe comorbid medical conditions (e.g., uncontrolled asthma, autoimmune disease, malignancy).\n* Pregnancy or breastfeeding.\n* Use of systemic corticosteroids, antibiotics, or other medications that may significantly alter sinusitis symptoms within 4 weeks prior to enrollment.\n* Participation in another clinical trial within the past 30 days.","65 Years",{"count":55,"type":21},30,[57],"NA","This double-blind, randomized controlled trial (BEE-SONIC) aims to evaluate the efficacy of bee venom phonophoresis in the treatment of chronic sinusitis. Thirty adult patients (aged 18-65 years) with clinically diagnosed chronic or acute sinusitis will be randomized into two groups: the intervention group will receive bee venom phonophoresis using low-to-moderate intensity ultrasound, while the control group will receive standard care consisting of oral decongestants and saline nasal irrigation. Primary outcomes include improvement in symptom severity (SNOT-22, Visual Analog Scale) and quality of life (SF-33). Secondary outcomes include reduction in facial pain, nasal congestion, and patient satisfaction. Data will be collected at baseline, midpoint, and post-intervention, and analyzed using paired t-tests and ANOVA. The study has received ethics approval from Sinai University's Human Research Ethics Committee, and informed consent will be obtained from all participants.",[27,60,61],"Acute Sinusitis","Rhinosinusitis",[30,63,64],"Rhinosinusitis, Chronic","Rhinosinusitis, Acute","NOT_YET_RECRUITING","2026-05-05",{"date":68,"type":36},"2026-05-11",{"date":70,"type":21},"2026-05-15",{"date":72,"type":21},"2026-12-25",{"name":74,"class":43},"Sinai University"]